Keyphrases
Alzheimer's Disease
100%
Inappropriate Use
100%
Alzheimer's Dementia
100%
Acetylcholinesterase Inhibitors (AChEI)
100%
Donepezil
66%
Adverse Effects
33%
Clinical Application
33%
Placebo
33%
U.S. Food
33%
Placebo-controlled Study
33%
Long-term Efficacy
33%
Alanine Aminotransferase Level
33%
Rivastigmine
33%
Pharmacological Treatment
33%
Head-to-head Comparison
33%
Frequent Monitoring
33%
Neuropsychiatric Symptoms of Dementia
33%
Metrifonate
33%
Galanthamine
33%
Latrine
33%
Medicine and Dentistry
Patient with Alzheimer's Disease
100%
Acetylcholinesterase Inhibitor
100%
Donepezil
66%
Adverse Event
33%
Drug Therapy
33%
Clinician
33%
Placebo
33%
Cognition
33%
Alanine Aminotransferase
33%
Placebo-Controlled Study
33%
Symptomatic Treatment
33%
Treatment of Alzheimer's Disease
33%
Tacrine
33%
Rivastigmine
33%
Galantamine
33%
Metrifonate
33%
Neuroscience
Alzheimer's Disease
100%
Acetylcholinesterase Inhibitor
100%
Placebo
66%
Donepezil
66%
Adverse Effect
33%
Behavior Disorder
33%
Rivastigmine
33%
Alanine Aminotransferase
33%
Galantamine
33%
Treatment of Alzheimer's Disease
33%
Metrifonate
33%
Pharmacology, Toxicology and Pharmaceutical Science
Alzheimer's Disease
100%
Cholinesterase Inhibitor
100%
Donepezil
66%
Adverse Event
33%
Placebo
33%
Alanine Aminotransferase
33%
Placebo-Controlled Study
33%
Behavior Disorder
33%
Tacrine
33%
Galantamine
33%
Rivastigmine
33%
Metrifonate
33%